Tisagenlecleucel治疗成人复发或难治性弥漫大B细胞淋巴瘤
这项国际2期关键研究评估了中心化制备的tisagenlecleucel(靶向CD19的CAR T细胞疗法)在成人复发或难治性弥漫大B细胞淋巴瘤患者中的疗效与安全性,这些患者不适合或自体造血干细胞移植后疾病进展。93例输注患者的最佳总缓解率为52%(95%CI 41-62),完全缓解率40%,部分缓解率12%;12个月无复发生存率估计为65%(完全缓解患者为79%)。常见3/4级特别关注不良事件包括细胞因子释放综合征(22%)、神经系统事件(12%)、持续超过28天的血细胞减少(32%)、感染(20%)和发热性中性粒细胞减少(14%)。
要点
- 最佳总缓解率52%,完全缓解率40%,部分缓解率12%。
- 12个月无复发生存率65%,完全缓解患者为79%。
- 3/4级细胞因子释放综合征22%,神经系统事件12%。
核心结论
- 在成人复发或难治性弥漫大B细胞淋巴瘤中,tisagenlecleucel产生了高比例的持久缓解。
研究设计与样本
- 国际、2期关键研究,纳入不适合或自体造血干细胞移植后疾病进展的成人复发或难治性弥漫大B细胞淋巴瘤患者,接受中心化制备的tisagenlecleucel输注。
- 共93例患者接受输注并纳入疗效评估;主要终点为独立审查委员会判定的最佳总缓解率(完全或部分缓解的患者百分比)。
主要发现
- 最佳总缓解率为52%(95%CI 41-62),其中40%患者达完全缓解,12%达部分缓解。
- 缓解率在各预后亚组间一致。
- 首次缓解后12个月无复发生存率估计为65%,完全缓解患者中为79%。
- 输注至数据截止的中位时间为14个月(范围0.1-26)。
关键数值与推荐
- 3/4级特别关注不良事件:细胞因子释放综合征22%,神经系统事件12%,持续超过28天的血细胞减少32%,感染20%,发热性中性粒细胞减少14%。
- 3例患者在输注后30天内死于疾病进展;无死亡归因于tisagenlecleucel、细胞因子释放综合征或脑水肿。
- 缓解组间未发现肿瘤CD19或免疫检查点相关蛋白表达的差异。
临床怎么用
- 对于不适合或自体造血干细胞移植后进展的成人复发或难治性弥漫大B细胞淋巴瘤,tisagenlecleucel是可产生持久缓解的治疗选择。
- 需重点监测并管理细胞因子释放综合征、神经系统事件、持续血细胞减少、感染和发热性中性粒细胞减少等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
引用
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018. PMID: 30501490. doi:10.1056/NEJMoa1804980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。